NDA 020122 · Hospira INC
Nipent
Pentostatin · Injection · Nucleoside Metabolic Inhibitor
NovelPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Nov 3, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1991
Oct 11, 1991
Approved uses
2
Original approval plus efficacy supplements
Registered trials
61
5 Phase 3, 3 recruiting
FAERS reports
1,052
968 serious, 257 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING NIPENT should be administered under the supervision of a physician qualified and experienced in the use of cancer chemotherapeutic agents. The use of higher doses than those specified (see DOSAGE AND ADMINISTRATION ) is not recommended. Dose-limiting severe renal, liver, pulmonary, and CNS toxicities occurred in Phase 1 studies that used NIPENT at higher doses (20-50 mg/m 2 in divided doses over 5 days) than recommended. In a clinical investigation in patients with refractory chronic lymphocytic leukemia using NIPENT at the recommended dose in combination with fludarabine phosphate, 4 of 6 patients entered in the study had severe or fatal pulmonary toxicity. The use of NIPENT in combination with fludarabine phosphate is not recommended.
What it is approved for
From the label in effect Oct 19, 2026.
INDICATIONS AND USAGE NIPENT is indicated as single-agent treatment for both untreated and alpha-interferon-refractory hairy cell leukemia patients with active disease as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms.
Therapeutic areas: Cardiovascular and metabolic · Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 29, 1993 Supplement 1 · Efficacy
- Oct 11, 1991 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
- NIPENT · PENTOSTATIN 10MG/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Pentostatin" as an intervention, any sponsor and status, largest first.
National Cancer Institute (NCI)NIH
NCT02579967 · 354 participants (planned) · Start Nov 19, 2015 · Primary completion Dec 31, 2031
Drug: Immunosuppression Only Conditioning -Closed with amendment L; Reduced Intensity Conditioning and 2 more · For: Primary T-cell Immunodeficiency Disorders; Common Variable Immunodeficiency; Immune System Diseases and 2 more
Sites: Bethesda, Maryland; Minneapolis, Minnesota
- A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)Pivotal-lookingCompleted
Incyte CorporationIncyte (INCY)
NCT03112603 · 330 participants · Start Jun 29, 2017 · Primary completion May 8, 2020
Drug: Ruxolitinib; Extracorporeal photopheresis (ECP) and 8 more · For: Graft-versus-host Disease (GVHD)
Sites: Tucson, Arizona; Duarte, California; La Jolla, California · 191 sites in all
National Cancer Institute (NCI)NIH
NCT05470491 · 265 participants (planned) · Start Jan 26, 2023 · Primary completion Jul 30, 2027
Drug: RIC; GVHD prophylaxis and 2 more · For: HIV; Hematologic Malignancies
Sites: Bethesda, Maryland
- Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)Status unknown
Heidelberg UniversityAcademic, hospital or other
NCT00927797 · 185 participants (planned) · Start Feb 2005 · Primary completion Jan 2009
Drug: Cyclophosphamide, Pentostatin, Rituximab · For: Immunocytoma/Morbus Waldenström; B-Cell Non-Hodgkin's Lymphoma; B-Cell Chronic Lymphocytic Leukemia
- Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia PatientsPivotal-lookingCompleted
US Oncology ResearchIndustry
NCT00254163 · 184 participants · Start Dec 2003 · Primary completion Sep 2011
Drug: Fludarabine; Cyclophosphamide and 2 more · For: B-Cell Chronic Lymphocytic Leukemia
Sites: Ocoee, Florida; Terre Haute, Indiana; Westminster, Maryland · 11 sites in all
- Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00224874 · 180 participants · Start Sep 2005 · Primary completion Jan 2009
Drug: Etanercept; Mycophenolate Mofetil and 2 more · For: Graft vs Host Disease; Immune System Disorders
Sites: Duarte, California; San Diego, California; Stanford, California · 19 sites in all
- Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.Status unknown
East Valley Hematology and Oncology Medical GroupAcademic, hospital or other
NCT00131313 · 180 participants · Start Jan 2003
Drug: Nipent, Cytoxan, Rituxan · For: Chronic Lymphocytic Leukemia
Sites: Muscle Shoals, Alabama; Burbank, California; Concord, California · 52 sites in all
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT00506922 · 150 participants · Start Sep 2000 · Primary completion Nov 2009
Drug: Pentostatin; Tacrolimus and 1 more · For: Leukemia; Lymphoma
Sites: Houston, Texas
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- neutropenia78
- pyrexia72
- dyspnoea71
- diarrhoea62
- drug ineffective62
- off label use59
- pneumonia58
- sepsis57
- nausea55
- anaemia54
- thrombocytopenia54
- febrile neutropenia48
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 21 |
| 2005 | 57 |
| 2006 | 58 |
| 2007 | 46 |
| 2008 | 61 |
| 2009 | 27 |
| 2010 | 39 |
| 2011 | 60 |
| 2012 | 71 |
| 2013 | 74 |
| 2014 | 58 |
| 2015 | 34 |
| 2016 | 21 |
| 2017 | 61 |
| 2018 | 39 |
| 2019 | 63 |
| 2020 | 54 |
| 2021 | 59 |
| 2022 | 26 |
| 2023 | 19 |
| 2024 | 45 |
| 2025 | 38 |
| 2026 | 21 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Current · updated Nov 9, 2026
Nipent, Injection, 10 mg, single dose vial (NDC 0409-0801-01). Other
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Nipent (Pentostatin) · HCPCS J9268
2024 spending
$424K
Beneficiaries
53
167 claims
Per beneficiary
$8,008
2024 ASP limit $2,421.93 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $626,975 |
| 2021 | $618,018 |
| 2022 | $393,991 |
| 2023 | $781,403 |
| 2024 | $424,420 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma.
Dhakal B, Hari P, Chhabra S, et al. · J Immunother Cancer 2025 · Clinical Trial, Phase II, Multicenter Study
- Pentostatin in steroid-refractory acute graft-versus-host disease.
Bolaños-Meade J, Jacobsohn DA, Margolis J, et al. · J Clin Oncol 2005 · Clinical Trial, Clinical Trial, Phase I
- Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy.
Geyer MB, Rivière I, Sénéchal B, et al. · Mol Ther 2018 · Clinical Trial, Phase I, Research Support, N.I.H., Extramural
- Pentostatin treatment of cutaneous T-cell lymphoma.
Dearden C, Matutes E, Catovsky D · Oncology (Williston Park) 2000 · Clinical Trial
- Prospective Study of a Novel, Radiation-Free, Reduced-Intensity Bone Marrow Transplantation Platform for Primary Immunodeficiency Diseases.
Dimitrova D, Gea-Banacloche J, Steinberg SM, et al. · Biol Blood Marrow Transplant 2020 · Clinical Trial, Research Support, N.I.H., Extramural
- Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy.
O'Brien S, Ravandi F, Riehl T, et al. · Blood 2008 · Multicenter Study, Randomized Controlled Trial
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.